BiotechTube

LY518674

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Syndrome X

Conditions

Metabolic Syndrome X

Trial Timeline

Jan 1, 2006 → Nov 1, 2006

NCT ID
NCT00327002

About LY518674

LY518674 is a phase 2 stage product being developed by Eli Lilly for Metabolic Syndrome X. The current trial status is completed. This product is registered under clinical trial identifier NCT00327002. Target conditions include Metabolic Syndrome X.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00327002Phase 2Completed

Competing Products

20 competing products in Metabolic Syndrome X

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
85
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
77
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
77
14C-labeled YM178Astellas PharmaPhase 1
33
TRC150094Torrent PharmaceuticalsPhase 1/2
41
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
77
Metformin + PlaceboEli LillyApproved
85
Tirzepatide + SemaglutideEli LillyPre-clinical
23
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
85
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaApproved
85
AZD2693 + PlaceboAstraZenecaPhase 1
33
RosuvastatinAstraZenecaPhase 3
77
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
77
rosuvastatinAstraZenecaApproved
85
EfinopegdutideMerckPhase 2
52
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
52
Vericiguat + PlaceboMerckPhase 2
52
MetforminMerckPhase 2
52

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85